Goldman Sachs Maintains Buy on HCA Healthcare, Lowers Price Target to $281
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Jamie Perse maintains a Buy rating on HCA Healthcare (NYSE:HCA) but has lowered the price target from $329 to $281.
October 30, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a Buy rating on HCA Healthcare but lowered the price target from $329 to $281.
The news is directly related to HCA Healthcare. While the Buy rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100